1 Barista I, Romaguera JE, Cabanillas F. Mantle-cell lymphoma. The Lancet Oncology. 2001;2(3):141-8.
2 Williams ME, Densmore JJ. Biology and therapy of mantle cell lymphoma. Current opinion in oncology. 2005;17(5):425-31.
3 Bertoni F, Rinaldi A, Zucca E, Cavalli F. Update on the molecular biology of mantle cell lymphoma. Hematological oncology. 2006;24(1):22-7.
4 Lenz G, Dreyling M, Hiddemann W. Mantle cell lymphoma: established therapeutic options and future directions. Annals of hematology. 2004;83(2):71-7.
5 Witzig TE. Current treatment approaches for mantle-cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005;23(26):6409-14.
6 Vigouroux S, Gaillard F, Moreau P, Harousseau JL, Milpied N. High-dose therapy with autologous stem cell transplantation in first response in mantle cell lymphoma. Haematologica. 2005;90(11):1580-2.
7 Tam CS, Wolf MM, Januszewicz EH, Prince HM, Westerman D, Seymour JF. Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies. Cancer. 2004;100(10):2181-9.
8 Decaudin D, Bosq J, Tertian G, Nedellec G, Bennaceur A, Venuat AM, et al. Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998;16(2):579-83.
9 Cohen BJ, Moskowitz C, Straus D, Noy A, Hedrick E, Zelenetz A. Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma. Leukemia & lymphoma. 2001;42(5):1015-22.
10 McLaughlin P, Hagemeister FB, Romaguera JE, Sarris AH, Pate O, Younes A, et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1996;14(4):1262-8.
11 Lossos IS, Paltiel O, Polliack A. Salvage chemotherapy using a combination of fludarabine and cyclophosphamide for refractory or relapsing indolent and aggressive non-Hodgkin's lymphomas. Leukemia & lymphoma. 1999;33(null):155-60.
12 Thomas DW, Owen RG, Johnson SA, Hillmen P, Seymour JF, Wolf MM, et al. Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP. Leukemia & lymphoma. 2005;46(4):549-52.
13 Belch A, Kouroukis CT, Crump M, Sehn L, Gascoyne RD, Klasa R, et al. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Annals of oncology : official journal of the European Society for Medical Oncology. 2007;18(1):116-21.
14 Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006;24(30):4867-74.
15 Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005;23(4):667-75.
16 Strauss SJ, Maharaj L, Hoare S, Johnson PW, Radford JA, Vinnecombe S, et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006;24(13):2105-12.
17 O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005;23(4):676-84.
18 Hewamana S, Alghazal S, Lin TT, Clement M, Jenkins C, Guzman ML, et al. The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood. 2008;111(9):4681-9.
19 Duechler M, Linke A, Cebula B, Shehata M, Schwarzmeier JD, Robak T, et al. In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells. European journal of haematology. 2005;74(5):407-17.
20 Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999;17(4):1244.
21 Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005;105(7):2677-84.
22 Barr PM, Fu P, Lazarus HM, Horvath N, Gerson SL, Koc ON, et al. Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma. British journal of haematology. 2009;147(1):89-96.
23 Forstpointner R, Dreyling M, Repp R, Hermann S, Hänel A, Metzner B, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004;104(10):3064-71.
24 Pott C, Schrader C, Gesk S, Harder L, Tiemann M, Raff T, et al. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood. 2006;107(6):2271-8.
25 Ross SR, McTavish D, Faulds D. Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy. Drugs. 1993;45(5):737-59.
26 Rummel MJ, Al-Batran SE, Kim SZ, Welslau M, Hecker R, Kofahl-Krause D, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005;23(15):3383-9.
27 Friedberg JW, Vose JM, Kelly JL, Young F, Bernstein SH, Peterson D, et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood. 2011;117(10):2807-12.